JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

Search

Akebia Therapeutics Inc

Abrir

SetorSaúde

2.99 1.01

Visão Geral

Variação de preço das ações

24h

Atual

Mín

2.93

Máximo

3.03

Indicadores-chave

By Trading Economics

Rendimento

-5.9M

247K

Vendas

5.1M

62M

Margem de lucro

0.395

Funcionários

181

EBITDA

-6.1M

7.4M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+124.36% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-50M

838M

Abertura anterior

1.98

Fecho anterior

2.99

Sentimento de Notícias

By Acuity

64%

36%

328 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

Akebia Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

22 de out. de 2025, 22:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project -- Update

22 de out. de 2025, 22:13 UTC

Aquisições, Fusões, Aquisições de Empresas

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project

22 de out. de 2025, 21:20 UTC

Ganhos

Correction to IBM 3Q Sales Jump Article

22 de out. de 2025, 20:57 UTC

Ganhos

SAP Posts Higher 3Q Revenue, Operating Profit

22 de out. de 2025, 23:46 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

22 de out. de 2025, 23:46 UTC

Conversa de Mercado

Nikkei May Decline Amid U.S.-China Trade Tensions -- Market Talk

22 de out. de 2025, 23:41 UTC

Conversa de Mercado

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 de out. de 2025, 23:38 UTC

Conversa de Mercado

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 de out. de 2025, 23:15 UTC

Ganhos

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 4th Update

22 de out. de 2025, 22:28 UTC

Conversa de Mercado

Alcoa Cautions About Spending More on U.S. Smelters -- Market Talk

22 de out. de 2025, 22:02 UTC

Ganhos

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 3rd Update

22 de out. de 2025, 21:59 UTC

Aquisições, Fusões, Aquisições de Empresas

Williams Cos.: Entered Into 1.5 Mtpa LNG Offtake Obligation >WMB

22 de out. de 2025, 21:58 UTC

Aquisições, Fusões, Aquisições de Empresas

Williams Cos. to Buy 10% Interest in Louisiana LNG LLC >WMB

22 de out. de 2025, 21:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Williams Cos. to Buy 80% Ownership In, Become Operator of Driftwood Pipeline >WMB

22 de out. de 2025, 21:56 UTC

Aquisições, Fusões, Aquisições de Empresas

Williams Cos.: Strategic Partnership Entered With Woodside Energy to Invest in Louisiana LNG Project >WMB

22 de out. de 2025, 21:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Woodside: Williams to Assume LNG Offtake Obligations for 10% of Produced Volumes

22 de out. de 2025, 21:47 UTC

Ganhos

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 de out. de 2025, 21:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Woodside: Williams to Contribute Its Share of Capex for LNG Facility, Pipeline

22 de out. de 2025, 21:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Woodside Energy Says Williams Deals Worth US$378 Million Including Capital Reimbursement

22 de out. de 2025, 21:45 UTC

Aquisições, Fusões, Aquisições de Empresas

Woodside Energy to Sell 80% Interest in Driftwood Pipeline Co. to Williams

22 de out. de 2025, 21:45 UTC

Aquisições, Fusões, Aquisições de Empresas

Woodside Energy to Sell 10% Interest in Louisiana LNG Holding Co. to Williams

22 de out. de 2025, 21:28 UTC

Conversa de Mercado
Ganhos

Correction to Alcoa Tariff Market Talk

22 de out. de 2025, 21:25 UTC

Ganhos

Wall Street Wonders if Grail's Cancer Test Results Are a True Positive -- Barrons.com

22 de out. de 2025, 21:17 UTC

Ganhos

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 2nd Update

22 de out. de 2025, 21:09 UTC

Conversa de Mercado
Ganhos

Alcoa Says Delivery Fee Covering Tariff Costs -- Market Talk

22 de out. de 2025, 21:00 UTC

Conversa de Mercado

ESG Roundup: Market Talk

22 de out. de 2025, 20:59 UTC

Ganhos

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 de out. de 2025, 20:51 UTC

Ganhos

SAP Reports Mixed Earnings. The Stock is Down. -- Barrons.com

22 de out. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

22 de out. de 2025, 20:44 UTC

Ganhos

Kaiser Aluminum: For the Full Yr 2025, Now Expects Conversion Rev to Be Flat to Up 5% Yr-Over-Yr and Raises Adjusted EBITDA Outlook to Improve 20% to 25% Yr-Over-Yr >KALU

Comparação entre Pares

Variação de preço

Akebia Therapeutics Inc Previsão

Preço-alvo

By TipRanks

124.36% parte superior

Previsão para 12 meses

Média 7 USD  124.36%

Máximo 8 USD

Mínimo 6 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Akebia Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

3 ratings

3

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

2.345 / N/ASuporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

328 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat